Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AUY922/m2 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Escalation | EXPERIMENTAL | - |
| HER2 Positive | EXPERIMENTAL | - |
| ER+ breast cancer | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AUY922 2 mg/m2 | DRUG | - |
Inclusion Criteria: 1. Dose-escalation and MTD dose expansion arm: Patients with histologically confirmed, advanced malignant solid tumors whose disease has progressed on standard therapy or for whom no standard therapy exists. Breast cancer phase II expansion arms only: 1. Females patients ...
Top 20 of 92 competitors
AUY922 is an investigational small molecule being studied for multiple oncology indications, including advanced HER2-positive breast cancer, advanced solid tumors, advanced gastric cancer, non-small-cell lung cancer, and relapsed or refractory multiple myeloma. It is also being evaluated in stomach and esophageal neoplasms, metastatic gastric cancer with mutated PI3KCA protein, and HER2-overexpressing tumors.
AUY922 is an HSP90 inhibitor, a class of drugs that target the heat shock protein 90 chaperone. By inhibiting HSP90, AUY922 disrupts the folding and stability of client proteins involved in cancer growth, including HER2 and PI3KCA. This mechanism is being studied across several HER2-positive and PI3KCA-mutated tumor types.
AUY922 is being developed by Novartis AG, a global pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. Novartis is conducting clinical trials of AUY922 across multiple oncology indications, including breast cancer, gastric cancer, and solid tumors.
AUY922 is in Phase 2 clinical development. It has completed Phase 1 and Phase 2 trials, including a Phase 2 study in advanced gastric cancer. However, AUY922 is still investigational and has not been approved by regulatory authorities. It remains in active clinical development for several oncology indications.
AUY922 has been studied in several completed clinical trials, including NCT00526045, a Phase 1-2 study in advanced solid malignancies and breast cancer; NCT01084330, a Phase 2 trial in advanced gastric cancer; NCT01271920, a Phase 1 combination study with trastuzumab in HER2-positive breast cancer; and NCT01613950, a Phase 1 study combining AUY922 with BYL719 in gastric cancer.
AUY922 is also known by the generic name luminespib, though this alternative name is not provided in the available data. The drug is being developed by Novartis under the code AUY922. Readers searching for luminespib should note that it refers to the same investigational HSP90 inhibitor.